Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accumulated Depreciation (2016 - 2022)

Spyre Therapeutics (SYRE) has disclosed Accumulated Depreciation for 5 consecutive years, with $2.8 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Accumulated Depreciation rose 41.3% year-over-year to $2.8 million, compared with a TTM value of $2.8 million through Dec 2021, up 41.3%, and an annual FY2021 reading of $2.8 million, up 41.3% over the prior year.
  • Accumulated Depreciation was $2.8 million for Q4 2021 at Spyre Therapeutics, up from $2.0 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $2.8 million in Q4 2021 and bottomed at $752000.0 in Q4 2018.
  • Average Accumulated Depreciation over 4 years is $1.6 million, with a median of $1.5 million recorded in 2019.
  • The sharpest move saw Accumulated Depreciation surged 40.29% in 2019, then surged 87.96% in 2020.
  • Year by year, Accumulated Depreciation stood at $752000.0 in 2018, then skyrocketed by 40.29% to $1.1 million in 2019, then soared by 87.96% to $2.0 million in 2020, then soared by 41.3% to $2.8 million in 2021.
  • Business Quant data shows Accumulated Depreciation for SYRE at $2.8 million in Q4 2021, $2.0 million in Q4 2020, and $1.1 million in Q4 2019.